Epilepsy Drugs Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (First Generation Anti-Epileptics, Second Generation Anti-Epileptics, and Third Generation Anti-Epileptics), Distribution Channel (Hospital Pharmacy, Retail Pharmacy Stores, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
The epilepsy drugs market size was valued at US$ 7.768 billion in 2022 and is projected to reach US$ 10.705 billion by 2030; it is estimated to register a CAGR of 4.1% from 2022 to 2030. The epilepsy drugs market growth is primarily driven by the increasing prevalence of epilepsy and an increasing number of elderly people.
Epilepsy is a neurological condition that can cause seizures and affects millions of people globally. Epilepsy drugs are also known as anti-epileptic drugs (AEDs), which are commonly used for the treatment of epilepsy as it helps in the better management of seizures among epilepsy patients. Some of the patients with drugs resistance epilepsy opt for other treatment methods such as surgery and devices that are implanted in the brain to helps in seizure management.
Several Epilepsy Drugs Nearing Patent Expiration Creating Opportunities for Epilepsy Drugs Market Growth
Many patents expiries are anticipated in the epilepsy drugs market in the upcoming years. It is likely to increase the penetration of generic products to cut down healthcare expenses. This will generate additional opportunities for other market players. Below mentioned are some drugs that are nearing patent expiration in the next couple of years.
Company Patent Patent Expiration Date Ingredient Treatment
Sumitomo Pharma Co US9206135 April 21, 2026 ESLICARBAZEPINE ACETATE Partial-onset Seizures Epilepsy
GlaxoSmithKline US7919115 January 4, 2029 LAMOTRIGINE Epilepsy
Ucb Inc USRE38551 March 17, 2022 Lacosamide Epilepsy and Partial-onset Seizures
SK Biopharmaceuticals US7598279 October 30, 2027 CENOBAMATE Partial Epilepsies
SUPERNUS PHARMS US8877248 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US9555004 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US10314790 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US8663683 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US9622983 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US8298580 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US8992989 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US8889191 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US9549940 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US8298576 April, 2028 Sustained-release formulations of Topiramate Epilepsy
Treatment-Based Insights
The epilepsy drugs market, by treatment, is segmented into first generation anti-epileptics, second generation anti-epileptics, and third generation anti-epileptics. In 2022, the second generation anti-epileptics segment held the largest market share; the third generation anti-epileptics is estimated to register the fastest CAGR during 2022–2030. The second-generation AEDs include felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, rufinamide, stiripentol, tiagabine, topirate, topiramate, vigabatrin, and zonisamide. In North America and Europe, ZNS is also considered a second-generation drug. The higher cost of second-generation AEDs compared with first-generation drugs is a significant factor limiting their mention in formularies. The second-generation AEDs have a more favorable side-effect profile and a lower risk of teratogenesis compared with first-generation drugs. Many first-generation and several second-generation (AEDs) share a common feature of enzyme induction that can increase the metabolism of different substrates targeted by the cytochrome p450 enzyme, along with a decrease in the action of the inducer.
Distribution Channel-Based Insights
The epilepsy drugs market, by distribution channel, is segmented into hospital pharmacy, retail pharmacy stores, and others. In 2022, the hospital pharmacies segment held the largest market share; the retail pharmacy segment is anticipated to register the fastest CAGR during 2022–2030. Hospital pharmacies purchase pharmaceuticals from different companies and supply them to hospitals for outpatient or inpatient treatments. Hospital pharmacies usually offer therapeutic and critical care drugs that have applications in cardiology, neurology, urology, pathology, hematology, and dermatology. Hospital pharmacies are among the essential parts of the healthcare system of any country. These pharmacies maintain stocks of epilepsy drugs to ensure their ready availability for patients. Thus, hospital pharmacies hold a considerable size of the epilepsy drug market.
A few of the major primary and secondary sources referred to while preparing the report on the epilepsy drugs market are the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Center for Biotechnology Information (NCBI), Investor presentations and Annual Reports of Market players.
Epilepsy is a neurological condition that can cause seizures and affects millions of people globally. Epilepsy drugs are also known as anti-epileptic drugs (AEDs), which are commonly used for the treatment of epilepsy as it helps in the better management of seizures among epilepsy patients. Some of the patients with drugs resistance epilepsy opt for other treatment methods such as surgery and devices that are implanted in the brain to helps in seizure management.
Several Epilepsy Drugs Nearing Patent Expiration Creating Opportunities for Epilepsy Drugs Market Growth
Many patents expiries are anticipated in the epilepsy drugs market in the upcoming years. It is likely to increase the penetration of generic products to cut down healthcare expenses. This will generate additional opportunities for other market players. Below mentioned are some drugs that are nearing patent expiration in the next couple of years.
Company Patent Patent Expiration Date Ingredient Treatment
Sumitomo Pharma Co US9206135 April 21, 2026 ESLICARBAZEPINE ACETATE Partial-onset Seizures Epilepsy
GlaxoSmithKline US7919115 January 4, 2029 LAMOTRIGINE Epilepsy
Ucb Inc USRE38551 March 17, 2022 Lacosamide Epilepsy and Partial-onset Seizures
SK Biopharmaceuticals US7598279 October 30, 2027 CENOBAMATE Partial Epilepsies
SUPERNUS PHARMS US8877248 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US9555004 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US10314790 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US8663683 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US9622983 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US8298580 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US8992989 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US8889191 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US9549940 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US8298576 April, 2028 Sustained-release formulations of Topiramate Epilepsy
Treatment-Based Insights
The epilepsy drugs market, by treatment, is segmented into first generation anti-epileptics, second generation anti-epileptics, and third generation anti-epileptics. In 2022, the second generation anti-epileptics segment held the largest market share; the third generation anti-epileptics is estimated to register the fastest CAGR during 2022–2030. The second-generation AEDs include felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, rufinamide, stiripentol, tiagabine, topirate, topiramate, vigabatrin, and zonisamide. In North America and Europe, ZNS is also considered a second-generation drug. The higher cost of second-generation AEDs compared with first-generation drugs is a significant factor limiting their mention in formularies. The second-generation AEDs have a more favorable side-effect profile and a lower risk of teratogenesis compared with first-generation drugs. Many first-generation and several second-generation (AEDs) share a common feature of enzyme induction that can increase the metabolism of different substrates targeted by the cytochrome p450 enzyme, along with a decrease in the action of the inducer.
Distribution Channel-Based Insights
The epilepsy drugs market, by distribution channel, is segmented into hospital pharmacy, retail pharmacy stores, and others. In 2022, the hospital pharmacies segment held the largest market share; the retail pharmacy segment is anticipated to register the fastest CAGR during 2022–2030. Hospital pharmacies purchase pharmaceuticals from different companies and supply them to hospitals for outpatient or inpatient treatments. Hospital pharmacies usually offer therapeutic and critical care drugs that have applications in cardiology, neurology, urology, pathology, hematology, and dermatology. Hospital pharmacies are among the essential parts of the healthcare system of any country. These pharmacies maintain stocks of epilepsy drugs to ensure their ready availability for patients. Thus, hospital pharmacies hold a considerable size of the epilepsy drug market.
A few of the major primary and secondary sources referred to while preparing the report on the epilepsy drugs market are the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Center for Biotechnology Information (NCBI), Investor presentations and Annual Reports of Market players.
1. INTRODUCTION
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
3. RESEARCH METHODOLOGY
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. EPILEPSY DRUGS LANDSCAPE
4.1 Overview
4.2 PEST Analysis
4.2.1 Global PEST Analysis
5. EPILEPSY DRUGS MARKET - KEY INDUSTRY DYNAMICS
5.1 Market Drivers
5.1.1 Growing Prevalence of Epilepsy
5.1.2 Increasing Number of Elderly People
5.2 Market Restraints
5.2.1 Recall of Therapeutic Products
5.3 Market Opportunities
5.3.1 Several Epilepsy Drugs Nearing Patent Expiration
5.4 Future Trends
5.4.1 Increasing Product Approvals
5.5 Impact Analysis
6. EPILEPSY DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1 Epilepsy Drugs Revenue (US$ Mn), 2022 – 2030
7. GLOBAL EPILEPSY DRUGS MARKET – REVENUE AND FORECAST TO 2030 – BY TREATMENT
7.1 Overview
7.2 Epilepsy Drugs Market Revenue Share, by Treatment 2022 & 2030 (%)
7.3 First Generation Antiepileptics
7.3.1 Overview
7.3.2 First Generation Antiepileptics: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Second Generation Anti-epileptics
7.4.1 Overview
7.4.2 Second Generation Anti-epileptics: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Third Generation Anti-epileptics
7.5.1 Overview
7.5.2 Third Generation Anti-epileptics: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
8. GLOBAL EPILEPSY DRUGS MARKET – REVENUE AND FORECAST TO 2030 – BY DISTRIBUTION CHANNEL
8.1 Overview
8.2 Epilepsy Drugs Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
8.3 Hospital Pharmacy
8.3.1 Overview
8.3.2 Hospital Pharmacy: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Retail Pharmacy Stores
8.4.1 Overview
8.4.2 Retail Pharmacy Stores: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9. EPILEPSY DRUGS MARKET – REVENUE AND FORECAST TO 2030 – GEOGRAPHIC ANALYSIS
9.1 North America: Epilepsy Drugs Market
9.1.1 Overview
9.1.2 North America: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.3 North America: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.1.4 North America: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.1.4.1 US: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.4.1.1 Overview
9.1.4.1.2 US: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.4.1.3 US: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.1.4.1.4 US: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.1.4.2 Canada: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.4.2.1 Overview
9.1.4.2.2 Canada: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.4.2.3 Canada: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.1.4.2.4 Canada: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.1.4.3 Mexico: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.4.3.1 Overview
9.1.4.3.2 Mexico: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.4.3.3 Mexico: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.1.4.3.4 Mexico: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.2 Europe: Epilepsy Drugs Market
9.2.1 Overview
9.2.2 Europe: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.3 Europe: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.2.4 Europe: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.2.5 Europe: Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
9.2.5.1 Germany: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.1.1 Overview
9.2.5.1.2 Germany: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.1.3 Germany: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.2.5.1.4 Germany: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.2.5.2 France: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.2.1 Overview
9.2.5.2.2 France: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.2.3 France: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.2.5.2.4 France: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.2.5.3 UK: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.3.1 Overview
9.2.5.3.2 UK: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.3.3 UK: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.2.5.3.4 UK: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.2.5.4 Italy: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.4.1 Overview
9.2.5.4.2 Italy: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.4.3 Italy: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.2.5.4.4 Italy: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.2.5.5 Spain: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.5.1 Overview
9.2.5.5.2 Spain: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.5.3 Spain: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.2.5.5.4 Spain: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.2.5.6 Rest of Europe: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.6.1 Overview
9.2.5.6.2 Rest of Europe: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.6.3 Rest of Europe: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.2.5.6.4 Rest of Europe: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.3 Asia Pacific: Epilepsy Drugs Market
9.3.1 Overview
9.3.2 Asia Pacific: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
9.3.3 Asia Pacific: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.3.4 Asia Pacific: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.3.5 Asia Pacific: Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
9.3.5.1 China: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.1.1 Overview
9.3.5.1.2 China: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.1.3 China: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.3.5.1.4 China: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.3.5.2 Japan: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.2.1 Overview
9.3.5.2.2 Japan: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.2.3 Japan: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.3.5.2.4 Japan: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.3.5.3 India: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.3.1 Overview
9.3.5.3.2 India: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.3.3 India: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.3.5.3.4 India: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.3.5.4 Australia: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.4.1 Overview
9.3.5.4.2 Australia: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.4.3 Australia: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.3.5.4.4 Australia: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.3.5.5 South Korea: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.5.1 Overview
9.3.5.5.2 South Korea: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.5.3 South Korea: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.3.5.5.4 South Korea: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.3.5.6 Rest of Asia Pacific: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.6.1 Overview
9.3.5.6.2 Rest of Asia Pacific: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.6.3 Rest of Asia Pacific: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.3.5.6.4 Rest of Asia Pacific: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.4 Middle East & Africa Epilepsy Drugs Market
9.4.1 Overview
9.4.2 Middle East & Africa: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.3 Middle East & Africa: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.4.4 Middle East & Africa: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.4.4.1 South Africa: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.4.1.1 Overview
9.4.4.1.2 South Africa: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.4.1.3 South Africa: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.4.4.1.4 South Africa: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.4.4.2 Saudi Arabia: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.4.2.1 Overview
9.4.4.2.2 Saudi Arabia: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.4.2.3 Saudi Arabia: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.4.4.2.4 Saudi Arabia: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.4.4.3 UAE: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.4.3.1 Overview
9.4.4.3.2 UAE: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.4.3.3 UAE: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.4.4.3.4 UAE: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.4.4.4 Rest of Middle East & Africa: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.4.4.1 Overview
9.4.4.4.2 Rest of Middle East & Africa: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.4.4.3 Rest of Middle East & Africa: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.4.4.4.4 Rest of Middle East & Africa: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.5 South & Central America: Epilepsy Drugs Market
9.5.1 Overview
9.5.2 South & Central America: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
9.5.3 South & Central America: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.5.4 South & Central America: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.5.5 South & Central America: Epilepsy Drugs Market Share by Country – 2022 & 2030, (%)
9.5.5.1 Brazil: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.5.5.1.1 Overview
9.5.5.1.2 Brazil: Epilepsy Drugs Market- Revenue and Forecasts to 2030 (US$ Million)
9.5.5.1.3 Brazil: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.5.5.1.4 Brazil: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.5.5.2 Argentina: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.5.5.2.1 Overview
9.5.5.2.2 Argentina: Epilepsy Drugs Market- Revenue and Forecasts to 2030 (US$ Million)
9.5.5.2.3 Argentina: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.5.5.2.4 Argentina: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.5.5.3 Rest of South & Central America: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.5.5.3.1 Overview
9.5.5.3.2 Rest of South & Central America: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
9.5.5.3.3 Rest of South & Central America: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.5.5.3.4 Rest of South & Central America: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
10. EPILEPSY DRUGS MARKET–INDUSTRY LANDSCAPE
10.1 Overview
10.2 Growth Strategies in the Epilepsy Drugs Market
10.3 Inorganic Growth Strategies
10.3.1 Overview
10.4 Organic Growth Strategies
10.4.1 Overview
11. COMPANY PROFILES
11.1 UCB SA
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Novartis AG
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Pfizer Inc
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 GSK Plc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Abbott Laboratories
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Sanofi SA
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Sumitomo Pharma America Inc.
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Teva Pharmaceutical Industries Ltd
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Catalyst Pharmaceuticals Inc
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
11.10 Alkem Laboratories Ltd
11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Products and Services
11.10.4 Financial Overview
11.10.5 SWOT Analysis
11.10.6 Key Developments
12. APPENDIX
12.1 About Us
12.2 Glossary of Terms
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
3. RESEARCH METHODOLOGY
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. EPILEPSY DRUGS LANDSCAPE
4.1 Overview
4.2 PEST Analysis
4.2.1 Global PEST Analysis
5. EPILEPSY DRUGS MARKET - KEY INDUSTRY DYNAMICS
5.1 Market Drivers
5.1.1 Growing Prevalence of Epilepsy
5.1.2 Increasing Number of Elderly People
5.2 Market Restraints
5.2.1 Recall of Therapeutic Products
5.3 Market Opportunities
5.3.1 Several Epilepsy Drugs Nearing Patent Expiration
5.4 Future Trends
5.4.1 Increasing Product Approvals
5.5 Impact Analysis
6. EPILEPSY DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1 Epilepsy Drugs Revenue (US$ Mn), 2022 – 2030
7. GLOBAL EPILEPSY DRUGS MARKET – REVENUE AND FORECAST TO 2030 – BY TREATMENT
7.1 Overview
7.2 Epilepsy Drugs Market Revenue Share, by Treatment 2022 & 2030 (%)
7.3 First Generation Antiepileptics
7.3.1 Overview
7.3.2 First Generation Antiepileptics: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Second Generation Anti-epileptics
7.4.1 Overview
7.4.2 Second Generation Anti-epileptics: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Third Generation Anti-epileptics
7.5.1 Overview
7.5.2 Third Generation Anti-epileptics: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
8. GLOBAL EPILEPSY DRUGS MARKET – REVENUE AND FORECAST TO 2030 – BY DISTRIBUTION CHANNEL
8.1 Overview
8.2 Epilepsy Drugs Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
8.3 Hospital Pharmacy
8.3.1 Overview
8.3.2 Hospital Pharmacy: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Retail Pharmacy Stores
8.4.1 Overview
8.4.2 Retail Pharmacy Stores: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9. EPILEPSY DRUGS MARKET – REVENUE AND FORECAST TO 2030 – GEOGRAPHIC ANALYSIS
9.1 North America: Epilepsy Drugs Market
9.1.1 Overview
9.1.2 North America: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.3 North America: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.1.4 North America: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.1.4.1 US: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.4.1.1 Overview
9.1.4.1.2 US: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.4.1.3 US: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.1.4.1.4 US: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.1.4.2 Canada: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.4.2.1 Overview
9.1.4.2.2 Canada: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.4.2.3 Canada: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.1.4.2.4 Canada: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.1.4.3 Mexico: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.4.3.1 Overview
9.1.4.3.2 Mexico: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.4.3.3 Mexico: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.1.4.3.4 Mexico: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.2 Europe: Epilepsy Drugs Market
9.2.1 Overview
9.2.2 Europe: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.3 Europe: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.2.4 Europe: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.2.5 Europe: Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
9.2.5.1 Germany: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.1.1 Overview
9.2.5.1.2 Germany: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.1.3 Germany: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.2.5.1.4 Germany: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.2.5.2 France: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.2.1 Overview
9.2.5.2.2 France: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.2.3 France: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.2.5.2.4 France: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.2.5.3 UK: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.3.1 Overview
9.2.5.3.2 UK: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.3.3 UK: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.2.5.3.4 UK: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.2.5.4 Italy: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.4.1 Overview
9.2.5.4.2 Italy: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.4.3 Italy: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.2.5.4.4 Italy: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.2.5.5 Spain: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.5.1 Overview
9.2.5.5.2 Spain: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.5.3 Spain: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.2.5.5.4 Spain: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.2.5.6 Rest of Europe: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.6.1 Overview
9.2.5.6.2 Rest of Europe: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.6.3 Rest of Europe: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.2.5.6.4 Rest of Europe: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.3 Asia Pacific: Epilepsy Drugs Market
9.3.1 Overview
9.3.2 Asia Pacific: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
9.3.3 Asia Pacific: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.3.4 Asia Pacific: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.3.5 Asia Pacific: Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
9.3.5.1 China: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.1.1 Overview
9.3.5.1.2 China: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.1.3 China: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.3.5.1.4 China: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.3.5.2 Japan: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.2.1 Overview
9.3.5.2.2 Japan: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.2.3 Japan: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.3.5.2.4 Japan: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.3.5.3 India: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.3.1 Overview
9.3.5.3.2 India: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.3.3 India: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.3.5.3.4 India: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.3.5.4 Australia: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.4.1 Overview
9.3.5.4.2 Australia: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.4.3 Australia: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.3.5.4.4 Australia: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.3.5.5 South Korea: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.5.1 Overview
9.3.5.5.2 South Korea: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.5.3 South Korea: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.3.5.5.4 South Korea: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.3.5.6 Rest of Asia Pacific: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.6.1 Overview
9.3.5.6.2 Rest of Asia Pacific: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.6.3 Rest of Asia Pacific: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.3.5.6.4 Rest of Asia Pacific: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.4 Middle East & Africa Epilepsy Drugs Market
9.4.1 Overview
9.4.2 Middle East & Africa: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.3 Middle East & Africa: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.4.4 Middle East & Africa: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.4.4.1 South Africa: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.4.1.1 Overview
9.4.4.1.2 South Africa: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.4.1.3 South Africa: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.4.4.1.4 South Africa: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.4.4.2 Saudi Arabia: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.4.2.1 Overview
9.4.4.2.2 Saudi Arabia: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.4.2.3 Saudi Arabia: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.4.4.2.4 Saudi Arabia: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.4.4.3 UAE: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.4.3.1 Overview
9.4.4.3.2 UAE: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.4.3.3 UAE: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.4.4.3.4 UAE: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.4.4.4 Rest of Middle East & Africa: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.4.4.1 Overview
9.4.4.4.2 Rest of Middle East & Africa: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.4.4.3 Rest of Middle East & Africa: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.4.4.4.4 Rest of Middle East & Africa: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.5 South & Central America: Epilepsy Drugs Market
9.5.1 Overview
9.5.2 South & Central America: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
9.5.3 South & Central America: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.5.4 South & Central America: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.5.5 South & Central America: Epilepsy Drugs Market Share by Country – 2022 & 2030, (%)
9.5.5.1 Brazil: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.5.5.1.1 Overview
9.5.5.1.2 Brazil: Epilepsy Drugs Market- Revenue and Forecasts to 2030 (US$ Million)
9.5.5.1.3 Brazil: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.5.5.1.4 Brazil: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.5.5.2 Argentina: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.5.5.2.1 Overview
9.5.5.2.2 Argentina: Epilepsy Drugs Market- Revenue and Forecasts to 2030 (US$ Million)
9.5.5.2.3 Argentina: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.5.5.2.4 Argentina: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.5.5.3 Rest of South & Central America: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.5.5.3.1 Overview
9.5.5.3.2 Rest of South & Central America: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
9.5.5.3.3 Rest of South & Central America: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.5.5.3.4 Rest of South & Central America: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
10. EPILEPSY DRUGS MARKET–INDUSTRY LANDSCAPE
10.1 Overview
10.2 Growth Strategies in the Epilepsy Drugs Market
10.3 Inorganic Growth Strategies
10.3.1 Overview
10.4 Organic Growth Strategies
10.4.1 Overview
11. COMPANY PROFILES
11.1 UCB SA
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Novartis AG
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Pfizer Inc
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 GSK Plc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Abbott Laboratories
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Sanofi SA
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Sumitomo Pharma America Inc.
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Teva Pharmaceutical Industries Ltd
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Catalyst Pharmaceuticals Inc
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
11.10 Alkem Laboratories Ltd
11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Products and Services
11.10.4 Financial Overview
11.10.5 SWOT Analysis
11.10.6 Key Developments
12. APPENDIX
12.1 About Us
12.2 Glossary of Terms
